Loading
companiesCompany
Harbinger Health
Flagship-founded blood-test company launching RESOLVE, a multi-cancer detection test for people with symptoms who are waiting for a diagnosis.
Overview
RESOLVE targets the symptomatic diagnostic window rather than asymptomatic screening, with tissue-of-origin output; first products expected commercially in H2 2026 after a $100M raise (2025). PROCARES prospective validation ongoing; multiple AACR 2026 presentations on the Harbinger HX methylation platform.
Similar pages
- IdeaMulti-cancer blood test as the first step for patients with non-specific symptoms
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), The hardest cancers are found late.
- IdeaA urine DNA test to decide who with blood in the urine needs a camera test
Shares Positive predictive value (PPV), DNA methylation profiling, The hardest cancers are found late.
- IdeaA breath test to rule out cancer in people with vague symptoms
Shares Positive predictive value (PPV), The hardest cancers are found late.
- CompanyClearNote Health
Shares Multi-cancer early detection (MCED), DNA methylation profiling.
- TreatmentCancerguard
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), DNA methylation profiling.
- IdeaA cancer blood test for older people arriving at A&E with unexplained symptoms
Shares Multi-cancer early detection (MCED), The hardest cancers are found late.
- IdeaA ten-dollar blood test for the five cancers that kill most people in poorer countries
Shares Multi-cancer early detection (MCED), DNA methylation profiling, The hardest cancers are found late.
- TermCCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), DNA methylation profiling.